Follow The Filings

CVS CVS Health

CVS Health earnings company data as of 7:06 PM ET 10/30

  • 1 of 1 EPS beats
  • 3 Owners
  • Rank #46
  • Max 2.6%
  • Master 0.51%

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 1.61 — —
Rev — — —
FY2026 Q2 5 Aug EPS 1.87 2.31 Beat +23.5%
Rev — — —

Who owns this now

Largest portfolio weights among holders, up to 2.6% (Richard Pzena, Pzena Investment Management). Not free-float ownership.

All holders
  1. Richard Pzena Reduce 2.6%
  2. Kentucky Trust Co. Reduce 0.57%
  3. David Katz 0.04%

Insider trades

Open-market buys and sales by CVS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CVS insider trades
  • None no insider bought on the open market
  • $324M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Larry Robbins Director
    Sale
    $317M 3,372,000 shares at $94.15 41% of stake
    Traded May 19–21 Filed May 21
  2. Tilak Mandadi EVP, Chief Exp & Tech Officer
    Sale
    $6.2M 69,551 shares at $89.58 87% of stake
    Traded May 8 Filed May 11
  3. Steven H Nelson EVP and President, Aetna
    Buy
    $1,289 24 shares at $53.70 New stake
    Traded Jan 23, 2025 Filed Jan 27
  4. Heidi B Capozzi EVP and Chief People Officer
    Buy
    $4,589 80 shares at $57.36 +1600% to stake
    Traded Sep 9, 2024–Oct 23, 2024 Filed Oct 14, 2025

Also filed in the last 12 months, not counted as buying or selling: 24 stock grants, 17 share withholdings for taxes, and 2 sales back to the company.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02,5.07
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
DEF 14A DEFINITIVE PROXY STATEMENT
DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
SCHEDULE 13G/A —
8-K 5.02

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.